Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025 ; expected to be sufficient to fund operations into Q4 of